Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

Michal Alon; Rand Arafeh; Joo Sang Lee; Sanna Madan; Shelly Kalaora; Adi Nagler; Tereza Abgarian; Polina Greenberg; Eytan Ruppin; Yardena Samuels

doi:10.18632/oncotarget.26685

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

PDF | How to cite

Oncotarget. 2019; 10:1344-1344. https://doi.org/10.18632/oncotarget.26685

Metrics: PDF 1415 views | ?

Michal Alon¹, Rand Arafeh¹, Joo Sang Lee^2,3, Sanna Madan^2,3, Shelly Kalaora¹, Adi Nagler¹, Tereza Abgarian¹, Polina Greenberg¹, Eytan Ruppin^2,3 and Yardena Samuels¹

¹ Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel
² Center for Bioinformatics and Computational Biology, The University of Maryland, College Park, Maryland, USA
³ Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA

Published: February 12, 2019

This article has been corrected: The correct Acknowledgments information is given below:

ACKNOWLEDGMENTS

The authors thank Tamar Ziv and Arie Admon (The Smoler Proteomics Center, Technion, Israel) for the proteomic analysis. The authors also thank Antonella Di Pizio and Masha Y. Niv (The Hebrew University of Jerusalem, Israel) for performing the structural analysis on predicted NF1 cleavage sites. The authors also thank The De Botton Protein Profiling institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science for identifying the proteolytic product of NF1. The work was supported by Minerva Foundation Grant.

Original article: Oncotarget. 2018; 9:31264-31277. DOI: https://doi.org/10.18632/oncotarget.25805.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26685

Publication Alerts

Corrections:

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma